EDGAR Filing Documents for 0001558370-23-006757

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]:

SEC Accession No. 0001558370-23-006757

Filing Date

2023-04-26

Accepted

2023-04-26 09:29:46

Documents

138

Period of Report

2022-12-31

Document Format Files

Seq	Description	Document	Type	Size
1	20-F	casi-20221231x20f.htm iXBRL	20-F	3609201
2	EX-2.2	casi-20221231xex2d2.htm	EX-2.2	29497
3	EX-4.20	casi-20221231xex4d20.htm	EX-4.20	10429
4	EX-4.30	casi-20221231xex4d30.htm	EX-4.30	625152
5	EX-8.1	casi-20221231xex8d1.htm	EX-8.1	2242
6	EX-11.1	casi-20221231xex11d1.htm	EX-11.1	52511
7	EX-12.1	casi-20221231xex12d1.htm	EX-12.1	12713
8	EX-12.2	casi-20221231xex12d2.htm	EX-12.2	13204
9	EX-13.1	casi-20221231xex13d1.htm	EX-13.1	6744
10	EX-13.2	casi-20221231xex13d2.htm	EX-13.2	6908
11	EX-15.1	casi-20221231xex15d1.htm	EX-15.1	2031
12	GRAPHIC	casi-20221231x20f009.jpg	GRAPHIC	10639
13	GRAPHIC	casi-20221231x20f010.jpg	GRAPHIC	27567
14	GRAPHIC	casi-20221231xex11d1001.jpg	GRAPHIC	9474
15	GRAPHIC	casi-20221231xex4d30001.jpg	GRAPHIC	148668
16	GRAPHIC	casi-20221231xex4d30002.jpg	GRAPHIC	154846
17	GRAPHIC	casi-20221231xex4d30003.jpg	GRAPHIC	148112
18	GRAPHIC	casi-20221231xex4d30004.jpg	GRAPHIC	122683
	Complete submission text file	0001558370-23-006757.txt		16948994

Data Files

Seq	Description	Document	Type	Size
19	EX-101.SCH	casi-20221231.xsd	EX-101.SCH	103921
20	EX-101.CAL	casi-20221231_cal.xml	EX-101.CAL	96636
21	EX-101.DEF	casi-20221231_def.xml	EX-101.DEF	446116
22	EX-101.LAB	casi-20221231_lab.xml	EX-101.LAB	667612
23	EX-101.PRE	casi-20221231_pre.xml	EX-101.PRE	697629
132	EXTRACTED XBRL INSTANCE DOCUMENT	casi-20221231x20f_htm.xml	XML	3050546

Mailing Address 1701-1702, CHINA CENTRAL OFFICE TOWER 1 NO. 81 JIANGUO ROAD, CHAOYANG DISTRICT BEIJING F4 100025

Business Address 1701-1702, CHINA CENTRAL OFFICE TOWER 1 NO. 81 JIANGUO ROAD, CHAOYANG DISTRICT BEIJING F4 100025 86 10 6561 8789

CASI Pharmaceuticals, Inc. (Filer) CIK: 0001962738 (see all company filings)